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Abstract
Background: We recently examined the distribution of abdominal fat, dietary intake and biochemical data in
patients with nonalcoholic fatty liver disease (NAFLD) and found that non-obese NAFLD patients did not
necessarily exhibit insulin resistance and/or dysregulated secretion of adipocytokines. However, dietary cholesterol
intake was superabundant in non-obese patients compared with obese patients, although total energy and
carbohydrate intake was not excessive. Therefore, excess cholesterol intake appears to be one of the main factors
associated with NAFLD development and liver injury.
Methods: We reviewed a year of follow-up data of non-obese NAFLD patients treated with Niemann-Pick C1 like 1
inhibitor ezetimibe to evaluate its therapeutic effect on clinical parameters related to NAFLD. Without any dietary
or exercise modification, 10 mg/day of ezetimibe was given to 8 patients. In 4 of 8 patients, ezetimibe was
administered initially. In the remaining 4 patients, medication was switched from ursodeoxycholic acid to
ezetimibe.
Results: In each patient, body mass index was maintained under 25 kg/m
2 during the observation period. Serum
ALT levels significantly decreased within 6 months and in 4 patients levels reached the normal range (<30 U/L),
which was accompanied with at least a 10% decrease in serum total cholesterol and LDL-cholesterol. However,
ultrasonographic findings of fatty liver did not show obvious improvement for a year.
Conclusion: We conclude that the cholesterol absorption inhibitor ezetimibe can suppress hepatic injury in non-
obese patients with NAFLD and that ezetimibe may offer a novel treatment for NAFLD.
Background
Nonalcoholic fatty liver disease (NAFLD), which is char-
acterized by hepatic steatosis, is a common cause of
abnormal liver function and its incidence is increasing
in many countries. Many NAFLD patients progress to a
severe form of nonalcoholic steatohepatitis that can lead
to cirrhosis, hepatic failure and hepatocellular carcinoma
[1,2]. Although obesity and/or insulin resistance are
considered to be a common cause of NAFLD, a large
proportion of NAFLD patients are non-obese individuals
[3,4]. Because onset and progression of NAFLD seem to
be affected by nutritional intake, we have compared the
distribution of abdominal fat, dietary intake and bio-
chemical data between obese and non-obese patients
with NAFLD to identify potential nutritional factors that
affect NAFLD [5,6]. Waist circumference, total abdom-
inal fat levels and subcutaneous fat levels were signifi-
cantly higher in the obese group, whereas visceral fat
levels were not significantly different between the two
groups. Non-obese patients did not show overt insulin
resistance and serum levels of adipocytokines were not
abnormal. Although total energy and carbohydrate
intake tended to be higher in the obese group, dietary
cholesterol intake was significantly higher and intake of
polyunsaturated fatty acids (PUFAs) was significantly
lower in the non-obese group. Considering these results,
suppressing cholesterol absorption may offer a novel
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ingly, the Niemann-Pick C1 like 1 (NPC1L1) inhibitor
ezetimibe was a suitable candidate to test this hypothesis.
In this study, we evaluate the therapeutic effect of ezeti-
mibe on non-obese NAFLD patients from the viewpoints
of hepatic injury, dyslipidemia, and ultrasonographic fatty
change. Ezetimibe had a prompt and excellent clinical
effect on laboratory findings except for imaging.
Patients and methods
The study population included 8 patients (males:females
=6 : 2 ,a g e :4 9 . 5 0±1 0 . 7 6y e a r s )w i t hN A F L Dw h ow e r e
diagnosed at Kyushu Medical Center Hospital between
October 2007 and June 2008. All patients provided writ-
ten informed consent before entering the study. They
met the following criteria of NAFLD: (i) alcohol intake
<20 g/day; (ii) exclusion of other liver diseases; (iii) the
bright liver pattern with liver-kidney contrast and vascu-
lar blurring by echotexture, or the liver-to-spleen
attenuation ratio <0.9 on computed tomography. More-
over, they were classified as non-obese based on a body
mass index (BMI) of less than 25 kg/m
2.I nt h ee v a l u a -
tion of homeostasis model assessment-insulin resistance
(HOMA-IR), no patients were classified as insulin resis-
tance defined by HOMA-IR>2.5. Before enrollment,
other etiologies of chronic liver disease were ruled out
again in each patient. Neither dietary nor exercise ther-
apy was prescribed, and their lifestyle was unchanged.
Therefore, their body weight and BMI were kept stable
during the following therapy (Figure 1A). Four of
8 patients had not been treated with any medicines for
NAFLD and dyslipidemia, such as ursodeoxycholic acid
(UDCA), fibrates or statins. Another 4 patients had
received 600 mg/day of UDCA before ezetimibe treat-
ment. For these patients, medication of ezetimibe
(10 mg/day, orally) was started initially or to replace
UDCA. No other agents for liver diseases, dyslipidemia
or diabetes were used on the patients during ezetimibe
treatment. Only one patient was hypertensive and the
Ca-blocker, amlodipine, was continued. All of these
patients have continued follow-up at our center with
weight monitoring and estimates of physical activity.
Statistical analysis was performed using the Wilcoxon
signed rank-sum test (p < 0.05) and Pearson and Spear-
man correlations to compare biochemical variables. This
follow-up study was approved by the Kyushu Medical
Center Institutional Review Board for Human Subjects
Research.
Results
Background of the non-obese NAFLD patients examined
is shown in Table 1. UDCA had been administered in 4
patients; however, it had poor efficacy. In these patients,
UDCA was stopped just before the ezetimibe treatment.
The degree of liver injury was assessed by pretreatment
measurement of alanine aminotransferase (ALT), which
was elevated over 50 U/L in all patients. All patients
received 10 mg of oral ezetimibe daily for more than
12 months although serum cholesterol levels were not
morbidly high. None of the patients underwent subse-
quent therapy during the follow-up period. Six months
after starting ezetimibe, serum levels of ALT was sig-
nificantly decreased from baseline (70.125 ± 24.608 vs.
36.635 ± 19.405, p = 0.0135) and the levels were kept
constant for 12 months (70.125 ± 24.608 vs. 34.250 ±
12.612, p = 0.0021) (Table 1, Figure 1B). In 4 patients,
ALT levels dropped to within the normal range (<30
U/L) both 6 and 12 months after the start of therapy
(data not shown). Decline rates of ALT levels at 6 and
12 months were -45.25 ± 24.19% and -49.33 ± 16.09%,
respectively (Figure 2). Naturally, ezetimibe treatment
decreased serum levels of LDL-cholesterol by 17.10 ±
11.36% (at 6 months) and 18.28 ± 15.86% (at
12 months) (Figure 2), but HDL-cholesterol, triglycer-
ide and HOMA-IR levels were unchanged (Table 1).
There was no significant correlation between ALT and
LDL-cholesterol. Serum g-glutamyl transpeptidase
(GGT) levels also decreased (Table 1), but the differ-
ence was not significant. Clinical course of a represen-
tative case (48-year-old male) is presented in Figure 3.
Although quantification of hepatic fat content could
not be performed by liver biopsy or computed tomo-
graphy, no significant attenuation of fat was found
Figure 1 Changes of body mass index (BMI) (A) and serum
alanine aminotransferase (ALT) levels (B) during ezetimibe
treatment. Values at baseline, 6 months and 12 months are
presented. *p < 0.05.
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treatment (data not shown).
Discussion
The concept that the onset and development of NAFLD
are associated with obesity and over-intake of calories,
which are linked to oxidative stress and insulin resis-
tance, is commonly accepted. Therefore, investigation of
therapeutic interventions has largely focused on agents
that modify oxidative stress and insulin sensitivity. In
contrast, we recently investigated the contribution of
nutritional factors in non-obese individuals with NAFLD
and reported that superabundant dietary cholesterol and
decreased dietary PUFAs intake might contribute to
NAFLD development [5,6]. Not surprisingly, cholesterol
supply and fatty acid synthesis are associated on a
stream of liver × receptor a (LXRa)-sterol regulatory
element binding protein-1c (SREBP-1c) pathway. In
hepatocytes, LXRa regulates cholesterol and fatty acid
metabolism, and its endogenous agonistic ligands are
oxysterols [7-10]. We have previously examined expres-
sion of lipid metabolism-associated genes in NAFLD
liver [11-18]. As a result, despite cholesterol overload in
hepatocytes, cholesterol synthesis is activated in the
NAFLD liver, meaning cholesterol metabolism is dysregu-
lated in NAFLD. Surplus cholesterol may lead to increased
levels of oxysterols, activation of the LXRa-SREBP-1c
pathway and enhanced fatty acid synthesis. Furthermore,
up-regulation of LXRa expression was more noticeable in
non-obese rather than in obese NAFLD patients. These
results might reveal new targets for the treatment of
NAFLD. Of note, suppression of dietary cholesterol
absorption may be a feasible option to successfully treat
NAFLD, particularly in non-obese patients.
NPC1L1 located in the proximal jejunum and on the
canalicular aspect of the hepatocytes is essential for
the absorption/reabsorption of cholesterol and other
plant sterols from the intestine and liver [19]. Animal
knockout models of NPC1L1 or treatment with an
Figure 2 Changes of serum alanine aminotransferase (ALT) and
LDL-cholesterol (LDL-C) levels during ezetimibe treatment.
Decrease (%) from baseline is presented at 6 and 12 months after
the treatment initiation. *p < 0.05 compared with baseline.
Figure 3 Clinical course of a representative case.A L T ,a l a n i n e
aminotransferase; GGT, g-glutamyl transpeptidase; LDL-C, LDL-
cholesterol; HDL-C, HDL-cholesterol; TG, triglyceride; BMI, body mass
index, HOMA-IR, homeostasis model assessment-insulin resistance.
Table 1 Clinical characteristics of patients, before and during ezetimibe treatment
Baseline 6 months 12 months
Body mass index (kg/m
2) 23.03 ± 2.04 22.81 ± 2.34 22.84 ± 2.17
ALT (IU/L) 70.13 ± 24.61 36.64 ± 19.41* 34.25 ± 12.61*
GGT (IU/L) 115.00 ± 62.28 69.50 ± 28.49 68.38 ± 28.28
Total cholesterol (mg/dL) 212.00 ± 49.01 192.25 ± 30.68* 191.38 ± 28.61*
Triglyceride (mg/dL) 98.88 ± 34.22 89.88 ± 31.56 94.88 ± 30.62
HDL-cholesterol (mg/dL) 59.13 ± 11.81 58.25 ± 12.09 61.50 ± 12.51
LDL-cholesterol (mg/dL) 137.50 ± 34.59 113.13 ± 29.68* 111.00 ± 29.65*
HOMA-IR 2.31 ± 0.25 2.24 ± 0.14 2.17 ± 0.31
Data are shown as mean ± SD
ALT, alanine aminotransferase; GGT, g-glutamyl transpeptidase; HOMA-IR, homeostasis model assessment-insulin resistance
*p < 0.05 compared with baseline
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provides resistance against hepatic steatosis [20,21].
Accordingly, the NPC1L1 inhibitor ezetimibe, which is
expected to decrease intracellular cholesterol levels
and down-regulate/inactivate LXRa, can be used as
novel therapeutic option for NAFLD. Based on the
findings above, we tried to suppress cholesterol
absorption by oral administration of ezetimibe (10 mg/
day). We initiated the first pilot trial of ezetimibe with
12 months of follow-up in a group of non-obese
patients with NAFLD, although their serum cholesterol
levels were not morbidly high. No other medications
known to alter aminotransferases or liver histology in
NAFLD including statins, ursodiol or fibrates were
taken by these patients during the follow-up period.
Because the effects of confounding variables, especially
lifestyle modifications, should be minimized, no patient
h a da ne x e r c i s eo rd i e tp r o g r a m sf o rB M Ir e d u c t i o n .
As a result of ezetimibe treatment, all patients had a
sufficient biochemical response. Serum levels of ALT
and GGT as well as cholesterol were effectively low-
ered and the effect continued during the observation
period. Especially, ALT was lowered significantly and
in four of 8 patients its levels reached the normal
range. However, none of these patients had evidence of
ultrasonographic improvement within 12 months.
Although there is a possibility that ezetimibe treatment
improves insulin resistance, HOMA-IR levels were
unchanged during the treatment. It may be because all
patients in this study were non-obese and insulin resis-
tance was not found at the baseline.
Would ezetimibe also be effective in obese NAFLD
patients? Because diet and exercise therapies are usually
prescribed simultaneously to obese patients, it is difficult
to evaluate the effect of ezetimibe therapy indepen-
dently. Perhaps, clinical improvement with ezetimibe
alone may be insufficient because, in addition to choles-
terol, other factors such as total calories, carbohydrate
and visceral fat associated with adipocytokine levels and
insulin resistance have strong influence on NAFLD in
obese individuals. However, ezetimibe may still be a
promising means for treatment.
Conclusion
Although limited by a small number of patients, our
study represents the 12 months of follow-up for non-
obese patients who received ezetimibe treatment for
NAFLD. Our results indicate that inhibition of choles-
terol absorption has a suppressive effect on liver injury
in NAFLD patients without any lifestyle modifications.
We could not demonstrate an obvious reduction of
hepatic fat content in ultrasonographic findings within
the first year. But confirmatory evidence of improve-
ment in images awaits further study.
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